Ad
related to: new hep c treatment 2008
Search results
Results from the WOW.Com Content Network
Boceprevir (INN, trade name Victrelis) is a protease inhibitor used to treat hepatitis caused by hepatitis C virus (HCV) genotype 1. [2] [3] It binds to the HCV nonstructural protein 3 active site. [4] It was initially developed by Schering-Plough, [5] then by Merck after it acquired Schering in 2009. It was approved by the FDA in May 2011. [6]
In fact, the rate of new hepatitis C cases more than quadrupled over the last decade, according to a study conducted by the Centers for Disease Control and Prevention (CDC). Dr. Dr.
[5] [6] It works against all six types of hepatitis C. [4] At twelve weeks following treatment between 81% and 100% of people have no evidence of hepatitis C. [7] It is taken once a day by mouth with food. [4] [5] The most common side effects are headache, diarrhea, and tiredness. [7] [8] In those with a history of hepatitis B, reactivation may ...
Telaprevir (VX-950), marketed under the brand names Incivek and Incivo, is a pharmaceutical drug for the treatment of hepatitis C co-developed by Vertex Pharmaceuticals and Johnson & Johnson. It is a member of a class of antiviral drugs known as protease inhibitors . [ 3 ]
Ledipasvir is a drug for the treatment of hepatitis C that was developed by Gilead Sciences. [1] After completing Phase III clinical trials, on February 10, 2014, Gilead filed for U.S. approval of a ledipasvir/sofosbuvir fixed-dose combination tablet for genotype 1 hepatitis C. [2] [3] The ledipasvir/sofosbuvir combination is a direct-acting antiviral agent that interferes with HCV replication ...
Hepatitis C is a global disease that infects upwards of 150 million people worldwide, especially in older generations. [6] [3] Hepatitis C causes inflammation of the liver that eventually leads to diminished liver function or even failure. [7] Zepatier is indicated for treatment with or without use of ribavirin, as well. [5]
Sofosbuvir/velpatasvir, sold under the brand name Epclusa among others, is a fixed-dose combination medication for the treatment of hepatitis C in adults. [2] [5] [6] [7] It combines sofosbuvir and velpatasvir. [2] [5] [6] It is more than 90% effective for hepatitis C genotypes one through six. [2]
Sofosbuvir is a once-daily oral nucleotide analogue inhibitor for the treatment of chronic hepatitis C virus. Gilead Sciences has received FDA priority review status for its New Drug Application ...
Ad
related to: new hep c treatment 2008